The recently developed Graphene-based neurotechnology by ICN2 and partners, illustrating major potential for progression in neuroscience and therapeutic applications. (Artist’s rendering.) Courtesy: SciTechDaily.com
Pioneering Graphene-Based Neurotechnology: A Major Paradigm Shift
A revolutionary reconciliation of neuroscience and technology, the graphene-based neurotechnology spearheaded by ICN2 and its partners, holds the future promise for transformative stratagems within the neuroscience and medicinal fields promising high-fidelity neural interfaces and highly targeted nerve modulation.
This study, featured in the acclaimed scientific journal Nature Nanotechnology, showcases the potentiality of a novel and highly innovative graphene-based neurotechnology that has the power to usher in a paradigm shift in both neuroscience and applications in the medical field. The confluence of efforts by the Institut Català de Nanociència i Nanotecnologia (ICN2), the Universitat Autònoma de Barcelona (UAB), and several international partners culminated in this groundbreaking discovery, with the technology itself being further utilized for therapeutic applications by the spin-off INBRAIN Neuroelectronics.
Quintessential Graphene Technology: A Novel Paradigm
The European Graphene Flagship project provided a springboard for years of exhaustive research, allowing ICN2, in partnership with the University of Manchester, to architect EGNITE (Engineered Graphene for Neural Interfaces). The revolutionary technological platform, designed for precise, flexible, high-resolution neural interfaces, embodies hope for transformative shifts in the burgeoning arena of neuroelectronics and brain-computer interfaces.
With a solid foundation in the fabrication and medical translation of carbon nanomaterials, EGNITE delivers on expectations with its graphene microelectrodes, only 25 µm in diameter, showcasing sterling efficacy and efficiency as neural interfaces while adhering to the tried-and-tested fabrication standards of the semiconductor industry.
Preclinical Verification – An Exemplification of Functionality
The cutting-edge EGNITE technology underwent stringent preclinical trials involving renowned neuroscience and biomedical specialists in collaboration with ICN2, successfully demonstrating unparalleled precision and clarity in recording high-resolution neural signals. It surpassed expectations by enabling impeccably precise nerve modulation and has proven itself to be a significant potential contributor to the therapeutic relevance of neuroelectronic applications.
Scientific Collaboration: An Embodiment of Global Leadership
This remarkable technological advancement rests on the shoulders of the European initiative, the Graphene Flagship, and was led by the distinguished team comprising of ICN2 researchers Damià Viana (currently associated with INBRAIN Neuroelectronics), Steven T. Walston (presently affiliated with the University of Southern California), and Eduard Masvidal-Codina. Under the expert guidance of ICREA Jose A. Garrido, the group leader of the ICN2 Advanced Electronic Materials and Devices Group, and ICREA Kostas Kostarelos, the group leader of the ICN2 Nanomedicine Lab this project has achieved significant milestones and has further been supported by several esteemed national and international institutions across the globe.
An Auspicious Profile for Clinical Translation
The patented and licensed EGNITE technology, as discussed in the Nature Nanotechnology article, is now on the precipice of refinement into clinical applications by INBRAIN Neuroelectronics, with preparations underway for the primordial human clinical trial of this revolutionary graphene technology.
The opportune advancements in the semiconductor industry of Catalonia coupled with strategic national planning have created a fertile environment, conducive to the rapid translation of this groundbreaking technology into viable clinical applications.
Concluding Reflections
Enabled by established semiconductor fabrication processes, graphene-based neurotechnology opens up a world of transformative potential, revolutionizing the world of neurology and medicine. The dedicated researchers and partners of ICN2 continue to refine and enhance the technology, with the ultimate aim of effecting tangible, therapeutic change in the scientific landscape.
Source: “Nanoporous graphene-based thin-film microelectrodes for in vivo high-resolution neural recording and stimulation,” Damià Viana, et al., Published 11 January 2024, Nature Nanotechnology.
Complete Article: View Full Text Here
